Cue Biopharma Reports Q3 2025 Financial Results

Cue Biopharma ( (CUE) ) has released its Q3 earnings. Here is a breakdown of the information Cue Biopharma presented to its investors.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing injectable therapeutics that selectively engage and modulate disease-specific T cells for treating autoimmune diseases and cancer. The company’s unique Immuno-STAT® platform aims to enhance efficacy while minimizing off-target effects, setting new standards in treatment. In its latest earnings report for the quarter ended September 30, 2025, Cue Biopharma highlighted several financial metrics and strategic developments. The company reported collaboration revenue of $2.1 million for the quarter, a decrease from $3.3 million in the same period last year. Operating expenses totaled $9.7 million, leading to a net loss of $7.4 million for the quarter. Despite the losses, the company raised $18.0 million through a public offering in April 2025, which bolstered its financial position. Cue Biopharma’s management remains focused on advancing its drug product candidates through clinical trials and exploring additional funding opportunities. The company is optimistic about its future prospects, driven by its recent collaboration and license agreement with ImmunoScape Pte. Ltd., which is expected to provide significant upfront payments. Looking ahead, Cue Biopharma aims to continue its research and development efforts, seeking regulatory approval and eventual commercialization of its innovative therapies.